Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists

of selected AHFTC specialists on the basis of background, specialized knowledge, skills, experience, and practice focus (right column). This distinction is particularly relevant to the patient care competencies and recognizes diversity in the focus of practice of AHFTC specialists. Some physicians may specialize in a particular aspect of AHFTC, such as mechanical circulatory support or cardiac transplantation, while others may adopt a practice focused on patients with chronic heart failure with a lesser (...) , there is a growing subspecialization career focus within AHFTC. Specifically, some practitioners limit the scope of their clinical activity to treating patients with advanced heart failure, including those who undergo implantation of a durable ventricular assist device or cardiac transplantation, while others focus on disease management of patients with less advanced heart failure. Thus, although maintenance of some AHFTC competencies is an expectation for all clinical AHFTC specialists, the maintenance

2020 International Society for Heart and Lung Transplantation

2. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Full Text available with Trip Pro

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis - Canadian Journal of Cardiology Go search , P159-169, February 01, 2020 Powered By Mendeley CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation (...) . DOI: Abstract In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis

2020 Canadian Cardiovascular Society

3. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction (Abstract)

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal (...) function in patients with acute heart failure and renal dysfunction at presentation.This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-guided group (n = 79) and in clinical evaluation in the usual-care group (n = 81). Changes in estimated glomerular filtration rate (eGFR) at 72 and 24 hours were the co-primary endpoints, respectively.The mean age

2020 EvidenceUpdates

4. Heart Failure - Systolic Dysfunction

or wall thickness. Gated SPECT may have better inter-observer reliability than echocardiography in assessing ejection fraction. However, the cost and radiation exposure support echocardiography as an appropriate initial evaluation. Functional testing. Exercise stress testing may have a role in the evaluation of some patients with heart failure. Exercise stress testing is useful in evaluating active and significant concomitant coronary artery disease and in assessing functional capacity (...) (dobutamine or dopamine) or phosphodiesterase inhibitors (milrinone) may have a role in the treatment of patients hospitalized for acutely decompensated heart failure who do not respond adequately or in a timely manner to diuretic therapy. Inotropic agents may increase cardiac output and decrease systemic and pulmonary vascular resistance. Although these therapies may improve symptoms and decrease hospitalizations, they are associated with increased mortality. Intermittent bolus or continuous home

2020 University of Michigan Health System

5. Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer?

been promising results that sacubitril/valsartan may also benefit patients with HFpEF. In the 2012 phase 2 PARAMOUNT trial comparing sacubitril/valsartan to valsartan in patients with an LVEF > 45% and a documented history of heart failure, ARNI therapy was shown to have beneficial effects on surrogate endpoints: biomarkers indicative of heart failure progression as well as echocardiographic evidence of cardiac remodeling. At 12 weeks of follow-up, ARNI therapy was associated with a significantly (...) populations who may demonstrate true benefit from the drug. Commentary by Dr. Adam Skolnick The main challenge in studying heart failure with preserved ejection fraction (HFpEF) is that there are at least four associated phenotypes: aging, obesity, pulmonary hypertension, and coronary artery disease. 16 Combining all phenotypes into one study runs the risk of missing a subtype of HFpEF for which there is benefit or harm. Future studies should attempt to study each phenotype of HFpEF separately in order

2020 Clinical Correlations

6. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Full Text available with Trip Pro

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine (...) Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions , 74 (23), 2893-2904 2019 Dec 10 Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Centre of Cardiovascular Research and Education

2020 EvidenceUpdates

7. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial

Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions , 140 (23), 1881-1891 2019 Dec 3 Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation

2020 EvidenceUpdates

8. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Am J Cardiol Actions 2019 Nov 19 [Online ahead of print] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Warren Alpert School of Brown University

2020 EvidenceUpdates

9. L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Full Text available with Trip Pro

L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Coronary artery bypass grafting reduces plasma L-carnitine and may impair the production of myocardial energy. L-carnitine supplementation may elevate plasma L-carnitine and increase cardiac mechanical efficiency. The objective of this study was to verify the recovery of preoperative plasma LC in patients with heart failure undergoing coronary artery (...) postoperative day, there was a reduction in plasma L-carnitine in groups A (17.4%) and B (14.4%). In the comparison between the groups, plasma L-carnitine was higher in group A than B in 10º (p = 0.024), 30º (p = 0.001), and 60º postoperative day (p = 0.008). Supplementation of L-carnitine at a daily oral dose of 50 mg / kg in patients with heart failure undergoing coronary artery bypass grafting may recover preoperative plasma L-carnitine within 10 days.

2019 Anais da Academia Brasileira de Ciencias Controlled trial quality: uncertain

10. Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report

-ventricular ejection fraction MCS Mental Health Composite Scale MLHFQ Minnesota Living with Heart Failure Questionnaire NYHA New York Heart Association OR odds ratio PCS Physical Composite Scale RCT randomized controlled trial SAE serious adverse event SF-36 Short Form (36) Health Survey SGB Sozialgesetzbuch (Social Code Book) TM telemedicine VAS visual analogue scale Extract of rapid report N19-01 Version 1.0 Telemonitoring in advanced cardiac failure 27 September 2019 Institute for Quality (...) of the heart to supply the organism with sufficient oxygen to ensure metabolism under both resting and exercise conditions [2]. It is a common disease in the older population [1] and is one of the most common causes of death in Germany [3]. Severity of cardiac failure is usually classified according to the New York Heart Association criteria (NYHA) [4]. However, the NYHA stage is not stable, i.e. it can change in one and the same person [4] and also relies heavily on the physician’s subjective assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure Full Text available with Trip Pro

Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heart failure patients from January 1996 through August 2019. Nineteen studies (9 (...) randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status

2019 EvidenceUpdates

12. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

(95% CI, 1.51–2.28) Similar in men and women … Retrospective cohort of Kaiser Permanente Northwest Database 8231 +DM, 8845 no DM Up to 6 rates (person-years): DM: 30.9/1000 No DM: 12.4/1000 Rate ratio, 2.5 (95% CI, 2.3–2.7) … … CAD indicates coronary artery disease; DM, diabetes mellitus; ellipses (…), not reported; HF, heart failure; HR, hazard ratio; MESA, Multi-Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Examination Survey; and RR, relative risk. The risk of HF (...) via vascular smooth muscle cell proliferation and inflammation ( ). DM is also associated with more atherogenic dyslipidemia, in which low-density lipoprotein cholesterol particles are more atherogenic, and with endothelial dysfunction, which promotes leukocyte and platelet adhesion, thrombosis, inflammation, and coronary plaque ulceration. Figure 1. Pathophysiology of heart failure in diabetes mellitus. The hyperglycemia, insulin resistance, and hyperinsulinemia that often accompany diabetes

2019 American Heart Association

13. Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

, Beanlands RSB, Mielniczuk LM . N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T levels are related to the extent of hibernating myocardium in patients with ischemic heart failure. Can J Cardiol . 2017 ; 33:1478–1488. doi: 10.1016/j.cjca.2017.06.012 AlBadri A, Lai K, Wei J, Landes S, Mehta PK, Li Q, Johnson D, Reis SE, Kelsey SF, Bittner V, et al. . Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from (...) , Wagoner LE, et al. . A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A . 2006 ; 103:11288–11293. doi: 10.1073/pnas.0509937103 Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol . 2009 ; 54:432–444. doi: 10.1016/j.jacc.2009.05.009 Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich

2019 American Heart Association

14. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Full Text available with Trip Pro

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF (...) status have not been reported. The objective was to explore the effects of EQW on secondary end points in patients with and without baseline HF and test the effects of EQW on recurrent HHF events.The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease, analyzed EQW effects on all-cause death, each major adverse cardiac event component, first HHF, and repeat HHF, by baseline HF status

2019 EvidenceUpdates

15. Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure

Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure 1 Public Summary Document Application No. 1387.2 – Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure Applicant: Impulse Dynamics and Life Systems Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance (...) with its Terms of Reference, visit the MSAC website 1. Purpose of application An application for the resubmission of an implantable pulse generator (IPG) delivering Cardiac Contractility Modulation (CCM) therapy for patients with chronic heart failure was received from Impulse Dynamics Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness

2019 Medical Services Advisory Committee

16. Improving Communication in Heart Failure Patient Care (Abstract)

Improving Communication in Heart Failure Patient Care Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heart failure (HF) or other diseases. To prevent shocks at the end of life, clinicians should discuss deactivating the defibrillation function.The purpose of this study was to determine if a clinician-centered teaching intervention and automatic reminders increased ICD deactivation discussions and increased device deactivation.In this 6-center (...) , single-blinded, cluster-randomized, controlled trial, primary outcomes were proportion of patients: 1) having ICD deactivation discussions; and 2) having the shocking function deactivated. Secondary outcomes included goals of care conversations and advance directive completion.A total of 525 subjects were included with advanced HF who had an ICD: 301 intervention and 224 control. At baseline, 52% (n = 272) were not candidates for advanced therapies (i.e., cardiac transplant or mechanical circulatory

2019 EvidenceUpdates

17. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study (Abstract)

Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk.All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using

2019 EvidenceUpdates

18. Sacubitril/valsartan for chronic heart failure with reduced ejection fraction

Sacubitril/valsartan for chronic heart failure with reduced ejection fraction '); } else { document.write(' '); } ACE | Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Search > > Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction - Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has (...) not recommended listing sacubitril/valsartan on the Medication Assistance Fund (MAF) for treating chronic heart failure with reduced ejection fraction because of uncertain cost-effectiveness and budget impact at the price proposed by the manufacturer. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

19. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Full Text available with Trip Pro

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal (...) dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality

2019 Lancet

20. Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Last updated: March 19, 2019 Project Number: RB1316-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure? Key Message Two randomized controlled trials regarding the clinical effectiveness of ivabradine for patients with stable chronic heart failure were identified. Files Rapid Response Summary of Abstracts Published : March 19, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review